NR3C2 and breast carcinoma: C3-CD-Man7 nanoparticles were able to encapsulate up to 12% of DOX, and the DOX-loaded system (DOX@C3-CD-Man7) efficiently delivered the drug to MR overexpressing MDA-MB-231 breast cancer cells in vitro and in vivo.